Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system
Abstract Background Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor that has been widely applied as a standard first-line treatment in advanced non-small cell lung cancer. However, the risk signals of osimertinib-related myotoxicity have not yet been full...
-д хадгалсан:
| Үндсэн зохиолчид: | , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | Inglês |
| Хэвлэсэн: |
BMC
2025-08-01
|
| Цуврал: | BMC Cancer |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://doi.org/10.1186/s12885-025-14743-3 |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|